Scienza e Tecnologia
TargEDys announces the publication of the first double-blind, randomized, placebo-controlled clinical trial showing Hafnia alvei's efficacy at an unprecedented level in weight loss and satiety
With an average of 3,6% weight loss in 12 weeks in the probiotic group, is dramatically more effective than any other probiotic studied in weight management, and this level of impact fills the gap between the sectors of food supplements and drugs. It also drives innovation in the probiotics field, shifting the approach to precision probiotics, with enhanced efficacy thanks to the precise understanding of the molecular mechanism of action.
can be found in the products ® and ® in France , Portugal , Italy and Slovenia , and TargEDys is looking for distribution partners to make this breakthrough solution for the prevention of obesity available to consumers worldwide.
, CEO of TargEDys, declares:
"This will be a game-changer in the sector of weight management, with finally a solution that meets consumers expectations in terms of safety and naturality, while also bringing a real, demonstrated efficacy based on molecular mimicry and the biochemical regulation of appetite."
®
TargEDys® is a commercial-stage French biotech specialized in the development of nutraceutical solutions for the control of appetite through microbiome interventions. The company is the fruit of 15 years of research on the microbiota conducted within academic laboratories. The company developed and started the commercialization of its first product based on the PreciBiomic strain HA4597™ and develops a product portfolio focusing on overweight, undernutrition and mental health, all based on the concept of precibiomic strains backed by a molecular mechanism of action and in vivo studies.
More information at www.targedys.com
Contact: Arnaud Faure & Nina Vinot ; bd@targedys.com
Logo: https://mma.prnewswire.com/media/1528261/Targedys_Logo.jpg